DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Thyrocare Technologies Limited — Agreements,Contracts,Arrangements,MOU-XBRL

NSE 1 hr ago·19 Aug 2026, 3:47 pm

Company NSE

Thyrocare Technologies has informed stock exchanges about entering into agreements, contracts, or arrangements, including a Memorandum of Understanding (MOU) related to XBRL reporting. The company has not disclosed the specific details or financial impact of these new deals at this time.

This announcement is a standard regulatory disclosure that signals new business developments. For investors, the significance depends on the nature of the agreements. While MOUs can indicate future growth or strategic partnerships, they are non-binding and do not guarantee immediate financial results.

Investors should wait for further clarification from the company regarding the scope and potential value of these arrangements. Keeping an eye on subsequent updates will be crucial to understanding how these new contracts might affect Thyrocare's future performance.